Evinacumab / Zodasiran (ANGPTL3 inhibitors)
Metabolic Health · ANGPTL3 inhibitor (mAb / RNAi)
Tier B
Bottom line
Read Off Label grades Evinacumab / Zodasiran (ANGPTL3 inhibitors) as B (6.6/10) based on strong evidence, med-high benefit magnitude, and a med-risk safety profile.
Evinacumab (Regeneron) approved for homozygous familial hypercholesterolemia.
Studied, labeled, or reported-use context: Evinacumab IV every 4 weeks; zodasiran SC — Rx (evinacumab approved for HoFH as Evkeeza); zodasiran investigational; not individualized guidance.
What the evidence says
Evinacumab (Regeneron) approved for homozygous familial hypercholesterolemia. Zodasiran (Arrowhead) RNAi: ARCHES-2 Phase 2b (NEJM 2024) showed deep TG/LDL/ANGPTL3 reductions; GATEWAY Phase 2 in HoFH sustained LDL -46% at 21 months; Phase 3 YOSEMITE began dosing 2025. LDL pathway distinct from PCSK9. Industry-sponsored.
Mechanism
ANGPTL3 inhibition (evinacumab = monoclonal antibody; zodasiran = RNAi) lowers LDL-C, triglycerides and HDL via a pathway independent of the LDL receptor, effective even in receptor-negative homozygous FH.
Studied, labeled, or reported dose & route
Evinacumab IV every 4 weeks; zodasiran SC
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Evinacumab / Zodasiran (ANGPTL3 inhibitors)'s effects?
- Read Off Label rates the evidence for Evinacumab / Zodasiran (ANGPTL3 inhibitors) as Strong and the benefit magnitude as med-high, producing an overall grade of B (6.6/10). Evinacumab (Regeneron) approved for homozygous familial hypercholesterolemia.
- What safety findings are reported for Evinacumab / Zodasiran (ANGPTL3 inhibitors)?
- Evinacumab / Zodasiran (ANGPTL3 inhibitors) has a med risk profile in the database. Med (evinacumab: nasopharyngitis, infusion reactions) Legal status: Rx (evinacumab approved for HoFH as Evkeeza); zodasiran investigational (Phase 3).
- What doses or routes are reported for Evinacumab / Zodasiran (ANGPTL3 inhibitors)?
- Evinacumab IV every 4 weeks; zodasiran SC This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Evinacumab / Zodasiran (ANGPTL3 inhibitors) work?
- ANGPTL3 inhibition (evinacumab = monoclonal antibody; zodasiran = RNAi) lowers LDL-C, triglycerides and HDL via a pathway independent of the LDL receptor, effective even in receptor-negative homozygous FH.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.